MAIAMAIA Biotechnology, Inc.

NYSE MAIABiotech.com


$ 3.21 $ 0.08 (2.54 %)    

Wednesday, 31-Jul-2024 12:53:41 EDT
QQQ $ 473.94 $ 0.06 (0.01 %)
DIA $ 408.46 $ 1.08 (0.27 %)
SPY $ 551.56 $ 8.81 (1.63 %)
TLT $ 94.83 $ 0.96 (1.02 %)
GLD $ 226.56 $ 4.03 (1.81 %)
$ 3.23
$ 3.22 x 200
-- x --
-- - --
$ 0.82 - $ 5.99
59,245
na
56.85M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-22-2022 06-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maia-biotechnologys-lung-cancer-drug-shows-promising-long-term-benefits-in-advanced-patients

MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NS...

 maia-biotechnology-reports-phase-2-results-for-lung-cancer-treatment-thio

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...

 maia-biotechnology-announces-year-to-date-highlights-and-achievements-including-clinical-progress-of-lead-candidate-thio-a-first-in-class-cancer-telomere-targeting-agent-for-non-small-cell-lung-cancer-nsclc

New science for cancer therapy drives powerful value propositionExceptional measures of efficacy by lead drug THIO in Phase 2 c...

 maia-biotechnology-announces-independent-director-ms-adelina-louie-ngar-yee-made-an-individual-purchase-of-19665-shares-and-warrants-for-19665-shares-of-common-stock

Original seed investor has remained top MAIA stockholderMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company...

 maia-biotechnology-announces-170940--share-purchase-by-director-adelina-louie-in-private-placement

Five independent members of MAIA's Board of Directors purchased shares in the offeringMAIA Biotechnology, Inc., (NYSE:MAIA)...

 maia-biotechnology-announces-133m-private-placement-of-06m-shares-at-2295share

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...

 maia-biotechnology-announces-170940-share-purchase-by-director-stan-smith-phd-in-a-29m-private-placement

Dr. Smith has participated in every MAIA funding roundMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company&#...

 maia-biotechnology-announces-efficacy-of-thio-combination-thio-180mg--cemiplimab-achieved-38-overall-response-rate-in-difficult-to-treat-third-line-non-small-cell-lung-cancer

Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell l...

 maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment-candidates-and-development-pipeline-in-letter-to-shareholders

THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION